1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU regulator says mRNA COVID-19 shots do not complicate pregnancies

01/18/2022 | 09:16am EDT

Jan 18 (Reuters) - A review by the European Union's drug regulator found that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, after it assessed data from studies involving around 65,000 pregnancies at different stages.

The European Medicines Agency said on Tuesday the review conducted by its COVID-19 task force also found that COVID-19 shots are as effective at cutting the risk of hospitalisation and death in pregnant people as in non-pregnant people. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -4.04% 132.06 Delayed Quote.-48.00%
ON SEMICONDUCTOR CORPORATION -2.49% 54.5 Delayed Quote.-19.76%
All news about MODERNA, INC.
05/24Moderna's CEO Stephane Bancel to Exercise Shares, Intends to Donate Proceeds to Charity
MT
05/24GLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
05/24WALL STREET STOCK EXCHANGE : Snap cut the rally short
05/24Rubius Therapeutics Names Noubar Afeyan Chairman; Shares Rise Pre-Bell
MT
05/24TRANSCRIPT : Moderna, Inc. Presents at UBS Global Healthcare Conference, May-24-2022 09:15..
CI
05/24MODERNA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/24Moderna testing potential monkeypox vaccines
RE
05/24Moderna CEO to Exercise 2013 Option, Donate Funds to Charity
DJ
05/24China's bet on homegrown mRNA vaccines holds back nation
AQ
05/23MODERNA : Statement Regarding Section 1498 Motion
PU
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 4,85x
Yield 2022 -
Capitalization 52 528 M 52 528 M -
EV / Sales 2022 1,56x
EV / Sales 2023 3,16x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 132,06 $
Average target price 212,69 $
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-48.00%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131